Sponsored by Division of Cancer Control and Population Sciences Division of Cancer Epidemiology and Genetics Office of Women’s Health National Cancer Institute,

Slides:



Advertisements
Similar presentations
PERSONALIZED MEDICINE: Planning for the Future You, Your Biomarkers and Your Rights.
Advertisements

1 CPCRN Mission To accelerate the adoption of evidence- based cancer prevention and control in communities.
Supported by grants from: National Human Genome Research Institute (ELSI) HG/AG (The REVEAL Study); National Institute on Aging AG (The MIRAGE.
SUPERSIZED NATION By Jennifer Ericksen August 24, 2007.
Project Overview NE FTCC Trainers’ Capacity Building Training May 24-25, 2010 at Mohonk Mountain House, New Paltz, NY Training Objectives: – Increase awareness.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Department of Health and Human Services Measuring Clinical Lab Ordering Quality: Theory and Practice Steven M. Asch MD MPH VA, RAND, UCLA April 29, 2005.
Breast Cancer Risk and Risk Assessment Models
Estimating the penetrances of breast and ovarian cancer in the carriers of BRCA1/2 mutations Silvano Presciuttini University of Pisa, Italy.
Genetic Susceptibility Risk Models in Clinical Decision Making Susan M. Domchek, MD Abramson Cancer Center University of Pennsylvania.
Prediction Models in Medicine Clinical Decision Support The Road Ahead Chapter 10.
Health Aspect of Disaster Risk Assessment Dr AA Abubakar Department of Community Medicine Ahmadu Bello University Zaria Nigeria.
Hss4303b – Intro to Epidemiology March 18, 2010 – Molecular & Genetic Epidemiology.
Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.
Decision Analysis as a Basis for Estimating Cost- Effectiveness: The Experience of the National Institute for Health and Clinical Excellence in the UK.
BRCA1 and BRCA2 Mutations and Breast Cancer: An Integrated Approach Using Four Epidemiologic Parameters Monica McClain, PhD. Assistant Director, Biometry.
Dietary intakes of calcium and vitamin D and risk of colorectal cancer in women Jennifer Lin, PhD Division of Preventive Medicine Brigham and Women’s Hospital.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Introduction to Molecular Epidemiology Jan Dorman, PhD University of Pittsburgh School of Nursing
Family History as a Screening Tool for Public Health and Preventive Medicine Paula W. Yoon, ScD, MPH Office of Genomics & Disease Prevention, CDC ACCE.
Thoughts on Biomarker Discovery and Validation Karla Ballman, Ph.D. Division of Biostatistics October 29, 2007.
Funding Priorities: National Cancer Institute Carly Parry, PhD, MSW National Cancer Institute.
BRCA1/2 Mutation Testing and Breast/Ovarian Cancer in the Ashkenazi Jewish Population Glenn E Palomaki, B.S. Foundation for Blood Research Scarborough,
Critical Appraisal of Clinical Practice Guidelines
Genomics Alexandra Hayes. Genomics is the study of all the genes in a person, as well as the interactions of those genes with each other and a person’s.
Knowledge, Cancer Fatalism and Spirituality as Predictors of Breast Cancer Screening Practices for African American and Caucasian Women Staci T. Anderson,
The Role of Local Specificity in the Interpretation of Small Area Estimation Benmei Liu Scott Gilkeson Gordon Willis Rocky Feuer 2012 FCSM Statistical.
Georgia Wiesner, MD CREC June 20, GATACAATGCATCATATG TATCAGATGCAATATATC ATTGTATCATGTATCATG TATCATGTATCATGTATC ATGTATCATGTCTCCAGA TGCTATGGATCTTATGTA.
What is Risk Prediction? Andrew N. Freedman, PhD Clinical and Translational Epidemiology Branch National Cancer Institute EGRP, DCCPS, NCI June 11, 2014.
1 Epidemiology in Groningen What is epidemiology Our department Projects in our department Special Oncology.
Multiple Choice Questions for discussion
Extending the Gail model for Breast Cancer Risk Prediction to Account for Modifiable Factors in the Italian Population. Calza S, Ferraroni M, Decarli A.
National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP)  Vision: a nation in which all people live healthy lives free from the devastation.
Criteria for Assessment of Performance of Cancer Risk Prediction Models: Overview Ruth Pfeiffer Cancer Risk Prediction Workshop, May 21, 2004 Division.
Adult-Onset Disease The Example of Colon Cancer Summer, 2012.
How do we know whether a marker or model is any good? A discussion of some simple decision analytic methods Carrie Bennette (on behalf of Andrew Vickers)
Translational Science in Cancer Health Disparities Research Peter Ujhazy, M.D., Ph.D. Program Director Translational Research Program Division of Cancer.
LESSON 9.5: TYPES OF STUDIES Module 9: Epidemiology Obj. 9.5: Compare & contrast different types of epidemiological studies.
Evidence-Based Public Health Nancy Allee, MLS, MPH University of Michigan November 6, 2004.
Conceptual Issues in Risk Prediction Colin B. Begg Memorial Sloan-Kettering Cancer Center.
Introduction of Department of Molecular Biology for Public Health in SCDC Ye Lu Shanghai Municipal Center for Disease Control & Prevention Shanghai Institute.
©Edited by Mingrui Zhang, CS Department, Winona State University, 2008 Identifying Lung Cancer Risks.
BOadicea Antonis Antoniou Cancer Research - UK
University of Iowa Cancer Prevention and Control Research Network Sue Curry, Ph.D., Principal Investigator This presentation was supported by Cooperative.
Other Intramural Training Opportunities at NCI Scientific DisciplinesProgram Population-based research, environmental & genetic determinants of cancer.
The Problem with Individual Risk Beverly Rockhill, Ph.D. Department of Epidemiology University of North Carolina, Chapel Hill.
1 Risk Assessment Tests Marina Kondratovich, Ph.D. OIVD/CDRH/FDA March 9, 2011 Molecular and Clinical Genetics Panel for Direct-to-Consumer (DTC) Genetic.
Modeling Efforts to Inform Countries’ Screening Decisions Ann Graham Zauber, Iris Vogelaar, Marjolein van Ballegooijen, Deb Schrag, Rob Boer, Dik Habbema,
Introduction Hereditary predisposition (mutations in BRCA1 and BRCA2 genes) contribute to familial breast cancers. Eighty percent of the.
Organization of statistical research. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and.
Epidemiology 242: Cancer Epidemiology Zuo-Feng Zhang, MD, PhD Fall Quarter, 2009.
Strategies to Improve Clinical Practice Through Guidelines: Experience from Recent Studies Michael Cabana (UCSF) Rebecca Beyth (University of Florida)
Breast Cancer Surveillance Consortium (BCSC): A Research Infrastructure sponsored by the National Cancer Institute Breast Cancer Risk Models William Barlow,
BIOSTATISTICS Lecture 2. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and creating methods.
Cancer 101: A Cancer Education and Training Program for [Target Population] Date Location Presented by: Presenter 1 Presenter 2.
CT Screening for Lung Cancer vs. Smoking Cessation: A Cost-Effectiveness Analysis Pamela M. McMahon, PhD; Chung Yin Kong, PhD; Bruce E. Johnson; Milton.
Department of Preventive Medicine Faculty of Public Health University of Debrecen General Practitioners’ Morbidity Sentinel Stations Program (GPMSSP) to.
Morristown Medical Center ~ Somerset County Department of Health Cancer Coordinator ~ Coalition Members at large Policy and Environmental Change ~Tobacco.
The National Cancer Research Network is part of the National Institute for Health Research CANCER GENETIC TRIALS Leicestershire, Northamptonshire and Rutland.
Economics of Complementary and Integrative Medicine: Where Do We Go From Here? Patricia M. Herman, ND, PhD, RAND Corporation IM4US Boston August 8, 2014.
Date of download: 7/7/2016 From: Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review.
Biomedical Data Science for Precision Medicine
Evidence-based Medicine
Northeast FTCC Region II
Coffee drinking and leukocyte telomere length: A meta-analysis
Lecture 6: Introduction to effect modification (part 2)
Biomedical Data Science for Precision Medicine
Mpundu MKC MSc Epidemiology and Biostatistics, BSc Nursing, RM, RN
Evidence-Based Public Health
Family History to Promote Individual Health
Presentation transcript:

Sponsored by Division of Cancer Control and Population Sciences Division of Cancer Epidemiology and Genetics Office of Women’s Health National Cancer Institute, National Institutes of Health, Department of Health and Human Services Cancer Risk Prediction Models: A Workshop on Development, Evaluation, and Application Washington, D.C. May 20-21, 2004

Workshop Overview and Objectives Andrew N. Freedman, Ph.D Applied Research Program, DCCPS, NCI

Risk Prediction Models for Cancer  Estimates the probability of developing cancer over a defined period of time Absolute Risk Assessment Models  Estimates the likelihood of detecting a mutation in a cancer susceptibility gene in a given family or individual Genetic Susceptibility Risk Models

Applications  Planning intervention trials  Estimating the population burden of disease  Clinical decision making and creating benefit/risk indices  Identifying individuals at high risk and designing prevention strategies

Development Risk Factors  Environmental  Demographic, reproductive, smoking, medications, etc.  Genetic  Family history  High penentrance alleles  Low penentrance polymorphisms  Clinical and Biological markers  Blood pressure, cholesterol, enzyme levels, protein expression, etc.  Interactions

Development Data  Cohort, case-control, nested case-control, family and clinical studies, SEER and population surveys  Expert opinion Risk Calculation  Empirical, logistic regression, proportional hazards, Bayesian analyses, log Incidence, Markov models/decision theory

Evaluation Reliability or Calibration  Ability of a model to predict incidence of a disease in a group of individuals Discriminatory Accuracy  Measures a model’s ability to discriminate at the individual level among those who develop disease from those who do not Internal Validity  Data-splitting, cross validation, bootstrapping External Validity  New independent sample

Absolute Risk Models Coronary Heart Disease  Framingham Coronary Risk Prediction Model (Kannel et al. Am J Cardiol, 1976) Breast Cancer  BCDDP “Gail” Model: (Gail et al. JNCI, 1989)  CASH “Claus: Model: (Claus et al. AJHG, 1991)  Group Health (Taplin et al. Cancer,1991)  DevCan (Feuer et al. JNCI, 1993)  NHS (Rosner et al. JNCI, 1996)

Risk models for predicting carrier status for cancer susceptibility genes BRCA1/2  Couch et al. NEJM,  Shattuck-Eidens et al. JAMA,  Frank et al. JCO,  BRCAPRO: Berry et al. JNCI 1997, Parmigiani, AJHG,  Hartge et al. AJHG, 1999.

Why this Workshop? Why Now?  Harvard Cancer Risk Index  Lung  Melanoma  Prostate  Colorectal  HNPCC (MLH1 and MSH2)  Breast  BRCA1/2  Extension of existing models 2005 NCI Bypass Budget, Genes and Environment  “Refine cancer risk prediction methods/models to integrate genetic and environmental determinants of cancer among diverse populations” Cancer Risk Prediction Models published in the last 2-3 years or currently in development

Personalized Medicine and Genetic Profiling  Collins FS, McKusick VA. Implications of the Human Genome Project for Medical Science. JAMA 2001;285: “By the year 2010, it is expected that predictive genetic tests will be available for as many as a dozen common conditions, allowing individuals who wish to know this information to learn their individual susceptibilities and to take steps to reduce those risks for which interventions are or will be available.”

Why This Workshop? Why Now?  Websites:  srab.cancer.gov/devcan/   www3.utsouthwestern.edu/cancergene/  Bcra.nci.nih.gov/   Books:  Handbook of Breast Cancer Risk Assessment  Handbook of Cancer Risk Assessment and Prevention  International Society of Cancer Risk Assessment and Management (ISC-RAM)  Companies in the US and UK offering testing of multiple genetic polymorphisms for genomic profiling for a number of chronic diseases

Current opportunities in Cancer Risk Prediction  Large cohort and case-control datasets and consortiums  Evidence for effective screening, intervention and prevention strategies in high risk individuals and in the general population  Promising new biomarkers  New risk prediction methodologies and evaluation techniques  Progress in research for communicating risk, decision- making and decision aids  Chemoprevention trials  Modeling cost-effectiveness and burden of disease by stratifying the population by risk and intervention

Important Questions: Application  What are the strengths and limitations of cancer risk prediction models?  For which applications are these risk prediction models most useful?  How useful are these risk prediction models at the individual level?  What discriminatory accuracy is needed to be useful in clinical decision-making?

Important Questions: Development  How much can we improve discriminatory power at the individual level with the addition of risk/genetic factors to the models?  Do we need to develop specific risk models for subgroups of the population (e.g. minorities)?  Are there genetic, biologic, hormonal or behavioral risk factors or markers that are particularly promising for risk prediction for cancer?  How can we effectively combine genetic, clinical, and biological risk factors with epidemiologic risk factors into absolute risk models?

Important Questions: Evaluation  What current models require validation? What quantitative criteria should be used to assess the performance of risk models for various purposes?  Are ROC curves the best measure of discriminatory accuracy?  How should one describe the uncertainties in predictions from model misspecification?  How transferable are absolute risk projections from one population to another?

Other Questions:  What resources are needed to improve cancer risk prediction models?  How should cancer risk prediction models be disseminated to health care providers, patients, and the public?  How can they be used effectively to improve cancer education and risk communication?  Monograph

Workshop Agenda Day 1  Session I: Applications of Cancer Risk Prediction Models  Session II: Poster Session  Session III: Goals and Issues in the Development of Cancer Risk Prediction Models for Various Purposes  Lunch: Lessons Learned from Cardiovascular Risk Models  Session IV: Risk Assessment Models for Predicting Cancer Susceptibility Genes and Cancer Risk  Session V: Breakout Sessions  Poster Session: Revisited Day 2  Session VI: Validation and Evaluation Methodology  Session VII: Report from Breakout Sessions

Breakout Sessions: Session I: Intervention studies, clinical decision-making, and population prevention strategies  Focus on breast cancer Session II: Intervention studies, clinical decision-making, and population prevention strategies  Focus on lung, CRC, melanoma and cancers other than breast Session III: Genetic susceptibility Session IV: Evaluation and validation

Thank You! Planning Committee  Rachel Ballard-Barbash, DCCPS, NCI  Graham Colditz, Harvard Medical School  Mitchell Gail, DCEG, NCI  Patricia Hartge, DCEG, NCI  Daniela Seminara, DCCPS, NCI  Mary Jane Kissel, Nova Research Corp.  Geoff Tobias, DCEG, NCI Sponsors  DCCPS, DCEG, OWH Participants Co-Chair  Ruth Pfeiffer, DCEG, NCI